Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia

Mette Kjær, Christof Geisen, Çiğdem Akalın Akkök, Agneta Wikman, Ulrich Sachs, James B Bussel, Kaspar Nielsen, Katarina Walles, Brian R Curtis, Gestur Vidarsson, Kerstin Järås, Bjørn Skogen

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)
70 Downloads (Pure)

Abstract

Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that development of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against HPA-1a and FNAIT is feasible. Anti-HPA-1a IgG can be obtained either by isolating immunoglobulin from already-immunized women or by development of monoclonal anti-HPA-1a antibodies. Here we discuss recent advances that may lead to the development of a prenatal and postnatal prophylactic treatment for the prevention of HPA-1a-associated FNAIT and life-threatening FNAIT-induced complications.

Original languageEnglish
Article number102712
JournalTransfusion and Apheresis Science
Volume59
Issue number1
Number of pages6
ISSN1473-0502
DOIs
Publication statusPublished - 2020

Keywords

  • FNAIT
  • HPA-1a
  • Prophylaxis

Fingerprint

Dive into the research topics of 'Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia'. Together they form a unique fingerprint.

Cite this